Loading...
•
Sep 30, 2024
AptarGroup Q3 2024 Earnings Report
AptarGroup reported strong Q3 2024 results with growth in proprietary drug delivery systems and increased demand for closure technologies.
Key Takeaways
AptarGroup's Q3 2024 results showed a 2% increase in both reported and core sales, driven by the Pharma and Closures segments. Net income increased by 19% to $100 million, and adjusted EPS rose by 6% to $1.49.
Reported and core sales increased by 2%.
Reported EPS increased 17% to $1.48, and adjusted EPS increased 6% to $1.49.
Reported net income increased 19% to $100 million.
Pharma segment delivered reported sales growth of 8% and core sales growth of 7%.
Revenue by Segment
Forward Guidance
Aptar anticipates a solid finish to a strong year, with top-line growth expected in Q4 despite some customer inventory adjustments. Pharma is expected to finish within its core sales long-term target range, and Closures expects a strong finish with healthy margin improvements. Beauty continues to focus on the bottom line in a tough macro environment.
Positive Outlook
- Top line is expected to grow in the fourth quarter.
- Pharma business should finish full year 2024 within its core sales long-term target range of 7-11%.
- Pharma segment will deliver solid, double-digit adjusted EBITDA growth in 2024 due in part to sales of higher value products and royalties.
- Closures segment has returned to growth and we expect a strong finish to 2024, with healthy adjusted EBITDA margin improvements over the prior year.
- Full year adjusted EPS would be in the range of $5.34 to $5.42, a double-digit increase over full year 2023.
Challenges Ahead
- Some customers have indicated seasonal inventory right-sizing in the beauty and cough & cold end markets.
- Beauty is battling a tough macro environment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...